Dr Reddys Laboratories (RDY) Payables (2009 - 2026)

Dr Reddys Laboratories (RDY) has reported Payables for 18 consecutive years, with $986.0 million the latest figure, recorded in Q1 2026.

• Quarterly Payables rose 14.39% year-over-year to $986.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $986.0 million (up 14.39% YoY) and the FY2026 annual result came in at $986.0 million, up 14.39% from the prior year.
• Payables advanced to $986.0 million in Q1 2026 per RDY's latest filing, from $862.0 million in the prior quarter.
• Over the last five years, Payables for RDY reached as high as $986.0 million in Q1 2026 and fell as low as $305.0 million in Q2 2022.
• A 5-year average of $588.6 million and a median of $524.0 million in 2024 frame the typical range for Payables.
• Annual changes were most pronounced in 2022 — Payables jumped 113.54% — and 2023, when it plunged 40.63%.
• Year by year, Payables stood at $305.0 million in 2022, then grew by 10.49% to $337.0 million in 2023, then jumped by 55.49% to $524.0 million in 2024, then soared by 64.5% to $862.0 million in 2025, then grew by 14.39% to $986.0 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $986.0 million, $862.0 million, and $524.0 million for Q1 2026, Q1 2025, and Q1 2024 respectively.